National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

apolizumab
A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:1D1O Anti-lymphoma Antibody
Monoclonal antibody 1D10
Monoclonal Antibody Hu1D10
US brand name:Remitogen
Abbreviations:MOAB 1D10
MoAb Hu1D10



Previous:apatinib, apaziquone, APC8015F, apixaban, Aplidin
Next:apomab, apoptosis inducer BZL101, apoptosis inducer GCS-100, apoptosis inducer GMX1777, apoptosis inducer MPC-2130

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov